Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.36 |
---|---|
High | 5.36 |
Low | 5.36 |
Bid | 5.42 |
Offer | 5.58 |
Previous close | 5.21 |
Average volume | 0.00 |
---|---|
Shares outstanding | 147.47m |
Free float | 144.41m |
P/E (TTM) | -- |
Market cap | 858.29m USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 07:03 GMT.
More ▼
Announcements
- Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
- Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
- Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
- Adaptive Announces IVDR Certification for clonoSEQ® in European Union
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
- Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
- Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
- Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
More ▼